And right now we are 2 minutes away from the end of the trading day. Romaine Bostick here with Katie Greifeld taking you through to that closing bell with a global simulcast. Carol Massar and Tim Stenovec join us now.Welcome to our audiences across all of our platforms television, radio, our partnership with YouTube here on a pretty wild Tuesday afternoon. Stocks opened higher. At one point, they saw a huge, huge plunge on the day Carol Massar But paring those losses heading into the close.Yeah, we did see ...

Q4 '25 Earnings Call February 3, 2026 Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance o ...

Core Insights - Merck has lowered its fourth-quarter expectations despite a strong performance from its Keytruda drug, indicating potential challenges ahead for the company [1] - The company has provided a disappointing earnings guidance for 2026, which may negatively impact its stock performance [1] Financial Performance - For the upcoming year, Merck anticipates adjusted earnings between $5 to $5.15 per share, falling short of analysts' expectations of $5.27 per share [1] Product Challenges - The guidance reflects ongoing difficulties with the Gardasil vaccine, which is affecting the company's overall outlook [1]

Core Viewpoint - Amgen reported fourth-quarter financial results that exceeded Wall Street expectations, primarily due to a 7% increase in drug sales and a lower tax rate [1] Financial Performance - The company achieved a 7% increase in drug sales, contributing significantly to its financial performance [1] - A lower tax rate positively impacted the overall financial results for the quarter [1]

Core Insights - Zentalis Pharmaceuticals is advancing the late-stage development of its first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment for ovarian cancer [1][3] - The management team will participate in a fireside discussion at Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11 in New York [1] Company Overview - Zentalis Pharmaceuticals focuses on developing innovative oncology treatments, particularly for ovarian cancer and various tumor types [3] - The company aims to provide a targeted, non-chemotherapy, orally available medicine that enhances treatment experience and outcomes for cancer patients [3] Event Information - A live webcast of the upcoming event will be available for at least 30 days after the event concludes, accessible under the "Events & Presentations" tab on the company's website [2]

Core Insights - The company reported total net revenue of $15.2 million for the fiscal 2026 second quarter [1] - Adjusted EBITDA was $(0.8) million, which includes investments of $30.0 million for the launch of EXXUA [1] - The company launched EXXUA™ (gepirone) extended-release tablets in December 2025, targeting the over $22 billion U.S. prescription major depressive disorder market [1] Financial Performance - Total net revenue for the quarter was $15.2 million [1] - Adjusted EBITDA was negative at $(0.8) million, reflecting the costs associated with the EXXUA launch [1] - The company had a cash balance of $30.0 million as of December 31, 2025 [1] Product Launch - EXXUA™ (gepirone) was launched in December 2025 as a key component of the company's commercial strategy [1] - The product aims to penetrate the significant U.S. market for major depressive disorder, valued at over $22 billion [1] Upcoming Events - The company will host a conference call and webcast on February 3, 2026, at 4:30 p.m. Eastern time to discuss the results [1]

Medicines Made for Life Nasdaq: AYTU February 2026 Actor portrayals. Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the futu ...

Core Viewpoint - Merck & Co., Inc. reported fourth-quarter results that met earnings expectations and slightly exceeded revenue forecasts, leading to a more than 2% increase in share price intraday [1] Group 1: Financial Performance - The company posted adjusted earnings per share of $2.04, aligning with analyst estimates [1] - Revenue increased by 5% year over year to $16.4 billion, surpassing the consensus estimate of $16.18 billion [1] Group 2: Growth Drivers - Growth was primarily driven by strong performance in oncology and animal health, along with contributions from newer products [2] - KEYTRUDA sales rose by 7% to $8.37 billion during the quarter [2] - Animal health revenue increased by 8% to $1.51 billion, supported by robust livestock demand [2] Group 3: Future Outlook - The 2026 outlook disappointed investors, with earnings forecasted at $5.00 to $5.15 per share, below analyst expectations of $5.63 [3] - A one-time charge of approximately $3.65 per share related to the acquisition of Cidara Therapeutics impacted the earnings forecast [3] - Revenue for 2026 is projected at $65.5 billion to $67.0 billion, slightly below the consensus of $67.58 billion [3] Group 4: Full-Year Sales - For the full year 2025, Merck reported worldwide sales of $65.0 billion, representing 1% growth, or 2% growth excluding foreign exchange [4] - KEYTRUDA generated $31.7 billion in annual sales [4] - Newer products WINREVAIR and CAPVAXIVE contributed $1.4 billion and $759 million, respectively [4]

Core Insights - Pfizer Inc. reported a decline in fourth-quarter revenue primarily due to reduced demand for COVID-19 products, although earnings exceeded analyst forecasts due to strong performance in vaccines and oncology [1][3] Revenue Performance - Operational revenue for the quarter ended December 31 decreased by 3% to $17.6 billion, surpassing Bloomberg consensus estimates of $16.94 billion [3] - Revenue from Pfizer's COVID-19 vaccine fell by 35% year over year, while sales of its antiviral COVID treatment dropped by 70%, attributed to lower infection rates and reduced utilization in the U.S. [1] Product Performance - Strong growth was observed in Abrysvo, Pfizer's respiratory syncytial virus vaccine for adults aged 18 to 59 at risk, with global sales increasing by 136% due to international demand and pricing [2] - Oncology biosimilars also showed significant growth, with sales rising by 76% year over year [2] Earnings and Guidance - Adjusted earnings per share for the quarter were reported at $0.66, exceeding expectations of $0.57 [3] - Pfizer reaffirmed its full-year guidance, projecting revenue between $59.5 billion and $62.5 billion and adjusted diluted EPS of $2.80 to $3.00 [3] Clinical Developments - Pfizer's experimental obesity treatment showed promising results, demonstrating up to 12.3% weight loss in non-diabetic patients during a mid-stage clinical trial [4]

Market Overview - Stocks declined on Tuesday, with the S&P 500 falling over 1% and the Nasdaq dropping approximately 2% due to a selloff in technology stocks [1] - Financial stocks, including Blue Owl Capital, KKR, Apollo Global Management, and BlackRock, also experienced declines as the market reacted to potential software losers from AI [1] Company-Specific Updates - Nvidia's stock fell more than 3% on Tuesday, maintaining a flat performance over the past six months; CEO Jensen Huang denied rumors of a fraying relationship with OpenAI during an interview with Jim Cramer [1] - Eli Lilly's shares dropped nearly 4% ahead of its earnings report, influenced by Novo Nordisk's disappointing guidance for 2026, which included a projected sales decline of 5% to 13% year over year [1] - Novo Nordisk's stock fell over 15% after announcing it expects lower sales in the U.S. due to price pressures and increasing competition, suggesting a potential loss of market share to Eli Lilly [1] Housing Market Insights - Housing-related stocks saw a rally following a report indicating efforts to make entry-level home buying more affordable, involving companies like Lennar and Taylor Morrison Home [1] - Despite the broader market decline, Home Depot's shares rose nearly 1%, indicating potential benefits from a revived housing market [1] Upcoming Earnings Reports - Key earnings reports expected after Tuesday's close include Advanced Micro Devices, Super Micro, Chipotle, Enphase Energy, Amgen, Amcor, Prudential Financial, Mondelez, and Corteva [1] - Notable reports before Wednesday's opening bell include GE Healthcare, Uber, Boston Scientific, Johnson Controls, AbbVie, Bunge, and Fortive [1]